

Summary of NMA Results: PFS of zanubrutinib compared with frontline treatments for TN CLL

	HR (95% CI)
Bendamustine + rituximab	0.42 (0.27, 0.65)
Obinutuzumab + chlorambucil	0.45 (0.23, 0.86)
Ibrutinib	1.07 (0.59, 1.94)
Chlorambucil + rituximab	0.22 (0.12, 0.41)